RxDoctor Payments Data

Andrew Lee, MD

Critical Care Medicine · Marlton, NJNPI 1417162090

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 192 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by GSK at 39.4% of the total. 2025 is the largest year on record at $1,178, 3.3 times the $354 reported in 2019.

$3,188in general payments, 2019–2025

Across 192 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$428
  • Regeneron Healthcare Solutions, Inc.$201
  • Amgen$137
  • Sanofi$107
  • Insmed, Inc.$102
  • plus $957 from 29 others

What the payments were for

  • Food & beverage$3,180100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,188 in reported general payments places this provider in the 80th percentile of 254 critical care medicine providers in New Jersey.

See all critical care medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$272,444
Medicare patients
871
Services billed
2,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter403$306,064
Breo ElliptaFluticasone/Vilanterol153$71,796
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr78$42,383
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$27,114
Spiriva RespimatTiotropium Bromide23$15,641
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$12,512
Albuterol Sulfate HfaAlbuterol Sulfate391$12,461
Incruse ElliptaUmeclidinium Bromide27$12,201
SymbicortBudesonide/Formoterol Fumarate34$9,139
Fluticasone-SalmeterolFluticasone Propion/Salmeterol79$8,361
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$3,875
Wixela InhubFluticasone Propion/Salmeterol26$3,384
BreynaBudesonide/Formoterol Fumarate11$2,113
Ventolin HfaAlbuterol Sulfate25$1,595
Roflumilast14$849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$1,256$432,444661 claims
AstraZenecaBreztri Aerosphere, Symbicort$428$36,25377 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$14$28,15243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 254 critical care medicine providers in New Jersey.

Other critical care medicine in Marlton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →